Thomas Lönngren, Strategic Advisor NDA Group, has been invited to present at a conversational workshop titled ‘Outlook for 2017 and beyond: Regulatory and Market Access Developments in Europe and US’ at BioMelbourne. The workshop will take place at BioMelbourne Network Board Room, Milton House, 25 Flinders Lane, Melbourne on 18th January.
This workshop will provide an outlook for 2017 on emerging trends and give companies the opportunity to present their case studies and questions in an intimate group setting. This exclusive session with Thomas Lönngren will also allow participants to draw on his experience as Executive Director of the European Medicines Agency as well as his present role advising pharmaceutical companies globally on regulatory aspects and market access around drug development.
Dr. Lönngren will also present on ‘Regulatory and Market Access Developments in Europe and the US’ at ARCS Australia. The seminar will take place at ARCS Training Room – Suite 802, 28 Clarke Street, Crows Nest NSW on 24th January.
This seminar will provide regulatory leaders and managers with an insight into regulatory and market access developments in Europe and US along with an Australian perspective on these trends.
Dr Lönngren will discuss recent regulatory and market access developments in Europe and US including:
- Regulatory development and alignment between FDA and EMA
- Market access in EU and US
- What does Brexit mean for the UK, EU and for medical technology and pharmaceutical companies?
- How will these developments affect Australian companies?